Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2021; 13(5): 611-619
Published online May 27, 2021. doi: 10.4254/wjh.v13.i5.611
Published online May 27, 2021. doi: 10.4254/wjh.v13.i5.611
Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report
Oriol Mirallas, Nadia Saoudi, Diego Gómez-Puerto, Jaume Capdevila, Medical Oncology Department, Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology, Barcelona 08035, Catalunya, Spain
Mar Riveiro-Barciela, Liver Unit, Department of Internal Medicine, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Catalunya, Spain
Xavier Merino, Cristina Auger, Radiodiagnostic Department, Vall d’Hebron University Hospital, Barcelona 08035, Catalunya, Spain
Stefania Landolfi, Maria Teresa Salcedo-Allende, Pathology Department, Vall d'Hebron University Hospital, Barcelona 08035, Catalunya, Spain
Laia Blanco, Xavier Molero, Hepatobiliopancreatic Surgery and Transplantation Department, Vall d'Hebron University Hospital, Barcelona 08034, Catalunya, Spain
Amparo Garcia-Burillo, Nuclear Medicine Department, Vall d'Hebron University Hospital, Barcelona 08035, Catalunya, Spain
Author contributions: Mirallas O, Saoudi N and Gómez-Puerto D were responsible for collecting the data, imaging, and writing the main text; Riveiro-Barciela M critically reviewed the text and helped write the acquired hepatocerebral degeneration text; Merino X and Auger C helped collect and describe the optimal images; Blanco L, Molero X, Salcedo-Allende MT, Landolfi S, Garcia-Burillo A, and Capdevila J are members of the multidisciplinary team of neuroendocrine tumors at Vall d’Hebron University Hospital who are taking care of patients, and critically reviewed and approved the manuscript; All authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and accompanying images.
Conflict-of-interest statement: Mirallas O, Saoudi N and Gómez-Puerto D declare that they have no competing interests funding related to this work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to it.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Oriol Mirallas, BSc, MD, Occupational Physician, Medical Oncology Department, Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology, Passeig de la Vall d'Hebron, 119, Barcelona 08035, Catalunya, Spain. omirallas@vhebron.net
Received: January 2, 2021
Peer-review started: January 2, 2021
First decision: January 18, 2021
Revised: February 4, 2021
Accepted: April 9, 2021
Article in press: April 9, 2021
Published online: May 27, 2021
Processing time: 137 Days and 22.6 Hours
Peer-review started: January 2, 2021
First decision: January 18, 2021
Revised: February 4, 2021
Accepted: April 9, 2021
Article in press: April 9, 2021
Published online: May 27, 2021
Processing time: 137 Days and 22.6 Hours
Core Tip
Core Tip: To the best of our knowledge, this is the first case report of acquired hepatocerebral degeneration in a metastatic small bowel neuroendocrine tumor long-term survivor, an uncommon irreversible extrapyramidal neurodegenerative condition encountered in patients with cirrhotic chronic liver disease, and resulting in widespread cerebral, basal ganglia, and cerebellar damage.